Related Experiment Video
Updated: Jul 12, 2026

Protocol for Relative Hydrodynamic Assessment of Tri-leaflet Polymer Valves
Published on: October 17, 2013
High rate of bleeding and arterial thrombosis in COVID-19: Saudi multicenter study
Abdulrahman Al Raizah1,2,3, Ahmed Al Askar4,5,6, Naila Shaheen6,7
1Division of Adult Hematology, Department of Oncology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, PO Box. 22490, 11426, Riyadh, Saudi Arabia. alzairaab@ngha.med.sa.
Insights
COVID-19 patients admitted to the ICU experienced higher rates of arterial and bleeding complications. Elevated D-dimer levels predict thrombotic complications, suggesting caution with intensified anticoagulation therapy.
Area of Science:
- Medical Research
- Infectious Diseases
- Cardiology
Background:
- Conflicting results exist regarding thrombotic event rates in COVID-19 patients.
- This study aimed to quantify thrombotic and bleeding events in hospitalized COVID-19 patients.
Purpose of the Study:
- To estimate the incidence of venous thromboembolism (VTE), arterial events, and bleeding complications in hospitalized COVID-19 patients.
- To identify risk factors for these events, specifically focusing on D-dimer levels.
Main Methods:
- A multicenter study involving 636 hospitalized patients with confirmed COVID-19.
- Data collected on VTE, arterial events, bleeding complications, and D-dimer levels.
- Comparison of event rates between intensive care unit (ICU) and non-ICU groups.
Main Results:
- Overall VTE rate was 1.8%, with significantly higher rates in the ICU (10.3%) compared to non-ICU (0.19%).
- Arterial events occurred at an overall rate of 2.2%, higher in ICU (8.4%) vs. non-ICU (0.94%).
- Bleeding events occurred at an overall rate of 1.7%, with higher rates in ICU (9.4%) vs. non-ICU (0.19%). Elevated baseline D-dimer was a significant predictor for VTE and composite events.
Conclusions:
- VTE rates in hospitalized COVID-19 patients may not be as high as previously suggested.
- ICU patients face elevated risks of arterial and bleeding complications.
- Baseline D-dimer levels can aid in identifying patients at risk for thrombotic complications. Intensified anticoagulation should be approached cautiously and evaluated in clinical trials.
Background:
Several observational studies have reported the rate of venous and arterial thrombotic events in patients infected with COVID-19, with conflicting results. The aim of this study was to estimate the rate of thrombotic and bleeding events in hospitalized patients diagnosed with Coronavirus disease 2019 (COVID-19).
Methods:
This was a multicenter study of 636 patients admitted between 20 March 2020 and 31 May 2020 with confirmed COVID-19 in four hospitals.
Results:
Over a median length of stay in the non-ICU group of 7 days and of 19 days in the ICU group, twelve patients were diagnosed with Venous thromboembolism (VTE) (1.8 %) (95 % CI, 1.1-3). The rate in the non-ICU group was 0.19 % (95 % CI, 0.04-0.84), and that in the ICU group was 10.3 % (95 % CI, 6.4-16.2). The overall rate of arterial event is 2.2 % (95 % CI, 1.4-3.3). The rates in the non-ICU and ICU groups were 0.94 % (95 % CI, 0.46-0.1.9) and 8.4 % (95 % CI, 5.0-14.0). The overall composite event rate was 2.9 % (95 % CI, 2.0-4.3). The composite event rates in the non-ICU and ICU groups were 0.94 % (95 % CI, 0.46-0.1.9) and 13.2 % (95 % CI, 8.7-19.5). The overall rate of bleeding is 1.7 % (95 % CI, 1.0-2.8). The bleeding rate in the non-ICU group was 0.19 % (95 % CI, 0.04-0.84), and that in the ICU group was 9.4 % (95 % CI, 5.7-15.1). The baseline D-dimer level was a significant risk factor for developing VTE (OR 1.31, 95 % CI, 1.08-1.57, p = 0.005) and composite events (OR 1.32, 95 % CI, 1.12-1.55, p = 0.0007).
Conclusions:
In this study, we found that the VTE rates in hospitalized patients with COVID-19 might not be higher than expected. In contrast to the risk of VTE, we found a high rate of arterial and bleeding complications in patients admitted to the ICU. An elevated D-dimer level at baseline could predict thrombotic complications in COVID-19 patients and may assist in the identification of these patients. Given the high rate of bleeding, the current study suggests that the intensification of anticoagulation therapy in COVID-19 patients beyond the standard of care be pursued with caution and would best be evaluated in a randomized controlled study.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Hemorrhagic Stroke ll: Pathophysiology
